SCHEMBL704608

SCHEMBL704608

Br[SiH2]C(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.41
F2 P00734 1/20 0.41
TSHR P16473 1/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
TRPA1 O75762 1/20 0.39
HTR2A P28223 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
CYP2D6 P10635 1/20 0.36
SRC P12931 1/20 0.36
LMNA P02545 2/20 0.35
HRH1 P35367 1/20 0.35
MTOR P42345 1/20 0.35
RAB9A P51151 1/20 0.35
GRM7 Q14831 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774509 0.75 DPP4 (0.45) DPP4F2TSHRCES2CES1
SCHEMBL1494253 0.73 DPP4 (0.43) DPP4F2TSHRHTR2ATAAR1
SCHEMBL842216 0.73 DPP4 (0.43) DPP4F2TSHRHTR2ATAAR1
SCHEMBL1494256 0.71 DPP4 (0.48) DPP4F2TSHRHTR2ATAAR1
SCHEMBL8386068 0.71 DPP4 (0.41) DPP4F2TSHRCES2CES1
SCHEMBL707749 0.71 DPP4 (0.41) DPP4F2TSHRHTR2ATAAR1
SCHEMBL8381565 0.71 DPP4 (0.41) DPP4F2TSHRHTR2ATAAR1
SCHEMBL245489 0.71 TSHR (0.48) DPP4F2TSHRHTR2ATAAR1
SCHEMBL2796779 0.71 DPP4 (0.41) DPP4F2TSHRHTR2ATAAR1
SCHEMBL434195 0.71 SRC (0.42) DPP4F2TSHRCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3092264-B1 METHOD FOR CAPPING MQ-TYPE SILICONE RESINS DOW SILICONES CORP (US) 2019-10-23 EP disclosed
US-9732191-B2 Method for capping MQ-type silicone resins DOW CORNING CORPORATION (US) 2017-08-15 US disclosed
EP-3092264-A1 METHOD FOR CAPPING MQ-TYPE SILICONE RESINS Dow Corning Corporation (US) 2016-11-16 EP disclosed
US-20160326320-A1 Method For Capping Mq-Type Silicone Resins DOW COMING CORPORATION (US) 2016-11-10 US disclosed
WO-2015105931-A1 METHOD FOR CAPPING MQ-TYPE SILICONE RESINS DOW CORNING CORPORATION (US) 2015-07-16 WO disclosed
US-8791221-B2 Addition-curable metallosiloxane compound DAICEL CORPORATION (JP) 2014-07-29 US disclosed
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND DAICEL CORPORATION (JP) 2013-10-10 US disclosed
US-8404876-B2 Process for producing nanoparticles 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-03-26 US disclosed
EP-2297172-B1 PROCESS FOR PRODUCING NANOPARTICLES 3M INNOVATIVE PROPERTIES CO (US) 2012-06-27 EP disclosed
US-8124239-B2 Silica film forming material, silica film and method of manufacturing the same, multilayer wiring structure and method of manufacturing the same, and semiconductor device and method of manufacturing the same FUJITSU LIMITED (JP) 2012-02-28 US disclosed
EP-1319666-A1 Novel antibacterial compounds Sankyo Company, Limited (JP) 2003-06-18 EP disclosed
EP-1319406-A1 Novel antibacterial compounds Sankyo Company, Limited (JP) 2003-06-18 EP disclosed
US-20030069204-A1 Strain of streptomyces SANKYO COMPANY LIMITED (JP) 2003-04-10 US disclosed
US-20030055297-A1 An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation ABBOTT LABORATORIES 2003-03-20 US disclosed
US-6472384-B1 Antimicrobial compounds SANKYO COMPANY, LIMITED (JP) 2002-10-29 US disclosed
WO-2002081441-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS ABBOTT LABORATORIES (US) 2002-10-17 WO disclosed
EP-1095947-A1 NOVEL ANTIBACTERIAL COMPOUNDS Sankyo Company Limited (JP) 2001-05-02 EP disclosed
EP-0284473-B1 PROCESS FOR THE PREPARATION OF SILYLATED CETENE ACETALS RHONE-POULENC CHIMIE (FR) 1991-05-29 EP disclosed
EP-0284473-A1 Process for the preparation of silylated cetene acetals RHONE-POULENC CHIMIE (FR) 1988-09-28 EP disclosed
US-4151327-A WATER AND OIL REPELLANT, DIMENSIONAL STABILITY, CLARITY OR OPACITY LAWTON WILLIAM R 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069204-A1 Strain of streptomyces O60361, CYP8B1, MRPS34 DPP4 1598/4885F2 4297/4885TSHR 3757/4885
US-20030055297-A1 An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation NEU4, NEU2, NEU1 DPP4 97/4885F2 2991/4885TSHR 762/4885
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND B2M, MSI2, MNS1 DPP4 4193/4885F2 1288/4885TSHR 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.